BNB Train is a BSC decentralized app (dApp) that generates profits through owner-renounced smart contracts leveraging flash loan arbitrage opportunities ...

Read More...

Recession risks mounting It’s been another week of significant volatility in financial markets, one in which European indices edged closer to bear market territory, oil prices hit a 10-year high around $120, and safe-haven gold came close to $2,000. The Russian invasion of Ukraine and the severe sanctions imposed on it by the West have […]

Whether you’re allocating resources more efficiently for web traffic, forecasting patient demand for staffing needs, or anticipating sales of a company’s products, forecasting is an essential tool across many businesses. One particular use case, known as cold start forecasting, builds forecasts for a time series that has little or no existing historical data, such as […]

Compass Mining beefed up its C-suite with hires focused on expansion

The post Latest in Crypto Hiring: Ledger Enterprise Has New Leader appeared first on Blockworks.

Haruko, a company that powers institutional access to digital assets worldwide, announced that it has closed a $10 million seed funding round to facilitate institutional crypto investors.

Customer service has always been important, but as the economy becomes more competitive, it is even more important that clients have a smooth...

Citizens Commercial Banking surveyed 260 corporate decision makers and found that 85% are looking to banks to provide real-time payment solutions — ranking it higher than other banking priorities such as lowest-cost financing. It’s a seismic shift resulting from the pandemic, Matthew Richardson, head of product solutions at Citizens Commercial Banking, tells Bank Automation News […]

US-based start-ups Growfin and PTO Exchange raise $1.4 million and $5.4 million, respectively.

The anti-racism VR simulation, co-developed by Bodyswaps and subject matter experts from George Brown College, is a great example of how immersive tech can do more

The post TRW: Bodyswaps shows that VR can do more appeared first on VRWorldTech Magazine.

DALLAS, TX, Mar 4, 2022 - (ACN Newswire) - Trintech, a leading global provider of integrated financial close automation software solutions for the Office of Finance, today announced the latest release of CadencyDirect which extends digital workflows for the Office of Finance with journal entry automation. This provides key stakeholders across the business with visibility and transparency into historically siloed disciplines to create a more connected organization that opens the door to enterprise-wide digital transformation.

"With this release, we are helping to make work flow more seamlessly for CFOs and their financial teams by helping them achieve enhanced visibility and control of critical financial data in order to handle risk with confidence," said Michael Ross, Chief Product Officer of Trintech. "By supporting a fully configurable end-to-end workflow, CadencyDirect eliminates common challenges found in manual approaches when creating financial data by delivering real-time visibility, control and validation across the financial close process and a better employee experience."

A key capability delivered with this release includes the ability for critical journal entry tasks and issues to trigger notifications and workflows throughout the entire enterprise, regardless of function, within the Now Platform(R). Examples include:

- Topside Journal Visibility: A real-time trigger will generate a workflow task and tracked notifications for specific Disclosure & Reporting team members

- High-Risk Journal Posting Visibility: A real-time trigger will generate a workflow task and tracked notifications for specific senior finance leadership that a high-risk journal has posted

- Internal Audit Journal Entry Rejection Visibility: A real-time trigger will generate a workflow task and tracked notifications for journal rejections while also mapping to controls framework, such as Sarbanes-Oxley, managed within SerivceNow GRC to ensure real-time visibility to compromised controls

CadencyDirect is certified as part of the ServiceNow Built on Now(TM) program that complements and extends financial operations management so that CFOs and their teams can digitize workflows across the financial close process - helping to reduce complexity and risk, accelerating the overall process, and driving a greater experience for the entire enterprise. The platform combines all financial close activities into a single, seamless process, including operational matching, intercompany transaction management, balance sheet reconciliations, journal entry management, close task management and compliance and provides a connected, collaborative ecosystem by leveraging a mature and very robust set of financial controls, along with deep automation and integration capabilities that seamlessly connects with leading ERPs such as SAP(R), Oracle(R), and NetSuite(R).

Whether you're an experienced ServiceNow user looking to synchronize your mature or in-progress digital transformation, or just starting your transformation journey, CadencyDirect is where Financial Transformation meets Digital Transformation. For more information, please contact either your appropriate ServiceNow or Trintech representative or go to www.trintech.com/CadencyDirect for more information.

About Trintech

Trintech Inc., a pioneer of Financial Corporate Performance Management (FCPM) software, combines unmatched technical and financial expertise to create innovative, cloud-based software solutions that deliver world-class financial operations and insights. From high volume transaction matching and streamlining daily operational reconciliations, to automating and managing balance sheet reconciliations, intercompany accounting, journal entries, disclosure reporting and bank fee analysis, to governance, risk and compliance - Trintech's portfolio of financial solutions, including Cadency(R) Platform, Adra(R) Suite, and targeted tools, ReconNET(TM), T-Recs(R), and UPCS(R), help manage all aspects of the financial close process. Over 3,500 clients worldwide - including the majority of the Fortune 100 - rely on the company's cloud-based software to continuously improve the efficiency, reliability, and strategic insights of their financial operations.

Headquartered in Dallas, Texas, Trintech has offices located across the United States, United Kingdom, Australia, Singapore, France, Germany, Ireland, the Netherlands and the Nordics, as well as strategic partners in South Africa, Latin America and the Asia Pacific. To learn more about Trintech, visit www.trintech.com or connect with us on LinkedIn, Facebook and Twitter.

ServiceNow, the ServiceNow logo, Now, Now Platform, and other ServiceNow marks are trademarks and/or registered trademarks of ServiceNow, Inc. in the United States and/or other countries.

Media Contact:
Kelli Shoevlin
214-957-5009
[email protected]

SOURCE: Trintech, Inc.

Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comTrintech, a leading global provider of integrated financial close automation software solutions for the Office of Finance, today announced the latest release of CadencyDirect which extends digital workflows for the Office of Finance with journal entry automation.

Hamilton, Bermuda, Mar 4, 2022 - (ACN Newswire) - Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, announced today that it has entered into an exclusive licensing and distribution agreement (the "Agreement") for Bentrio(TM), its nasal spray for protection against airborne viruses and allergens, with Nuance Pharma Ltd. ("Nuance") in Chinese Mainland, Hong Kong, Macau and South Korea (the "Territory").

Under the terms of the Agreement, Altamira will initially supply Bentrio(TM) to Nuance. Nuance will make an upfront payment of $1 million and pay to Altamira development and commercial milestones of up to $3 million and up to $19.5 million, respectively. Nuance will have the right to register and commercialize Bentrio(TM) in the Territory. In a second stage, Nuance will assume local production of the product for the Territory upon certain milestones. Once Nuance assumes local production of Bentrio(TM), it will pay to Altamira a staggered royalty on net sales in the Territory at a high-single to low-double-digit percentage.

"We are excited to greatly expand the distribution of Bentrio and further enlarge our footprint in Asia through this strategic collaboration with Nuance," said Thomas Meyer, Altamira Therapeutics' founder, Chairman and CEO. "As a fast growing, well capitalized company with a growing portfolio of products specifically for the treatment of respiratory disorders, Nuance is an ideal commercialization partner for this important and dynamic region. We are looking forward to working with the Nuance team to launch Bentrio."

"The prevalence of allergic rhinitis in the Chinese Mainland is particularly high, affecting some 246 million patients[1]," commented Mark G. Lotter, CEO and Founder of Nuance. "In addition, viral infections represent another high-volume opportunity for Bentrio in this region, so we are looking forward to launching this promising therapeutic to patients in the Chinese Mainland; as well as Hong Kong, Macau and South Korea. Bentrio(TM) fits well with Nuance's continuous strategic focus in respiratory space."

References
[1] https://doi.org/10.4168/aair.2019.11.2.156

About Bentrio(TM)

Bentrio(TM)(AM-301) is a drug-free nasal spray intended for personal protection against airborne viruses and allergens. Upon application into the nose, Bentrio(TM) forms a protective gel layer on the nasal mucosa. This thin film is designed to prevent the contact of viruses or allergens with cells; in addition, the composition serves to bind such particles and help with their discharge and to humidify the nasal mucosa. Together, this is designed to reduce the risk of upper respiratory tract viral infections and promote alleviation of allergic symptoms. In human nasal epithelium cells infected by SARS-CoV-2, Bentrio(TM) was shown to reduce the infectious viral load by more than 99% when used for prevention. Further, Bentrio(TM) was effective in slowing the growth of the viral titer when treatment started only 24 or 30 hours after infection. In allergy, a clinical investigation in a pollen challenge chamber demonstrated a significant reduction in the main symptoms of allergic rhinitis with the protective effect setting in rapidly and lasting for 4 hours.

About Nuance Pharma

Nuance Pharma is a patient-centric and innovation focused biopharmaceutical company, with both clinical and commercial stage assets. Founded by Mark Lotter in 2014, with the mission to address critical unmet medical needs in Greater China and Asia Pacific, Nuance has built a late clinical stage innovative portfolio, while maintaining a self-sustainable commercial operation. Focusing on specialty care, Nuance's portfolio represents a differentiated combination of commercial stage and innovative pipeline assets across respiratory, emergency care, and iron deficiency anemia. Through partnerships with global leading biopharma companies, Nuance has built a leading late-stage portfolio in respiratory and commercial stage portfolio in emergency care and iron deficiency anemia.

About Altamira Therapeutics

Altamira Therapeutics is dedicated to developing therapeutics that address important unmet medical needs. The Company is currently active in three areas: the development of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore(TM) / SemaPhore(TM) platforms; preclinical), nasal sprays for protection against airborne viruses and allergens (Bentrio(TM); commercial) or the treatment of vertigo (AM-125; Phase 2), and the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (Keyzilen(R) and Sonsuvi(R), Phase 3). The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Altamira Therapeutics Ltd. trade on the NASDAQ Capital Market under the symbol "CYTO."

Forward-looking Statements

This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira Therapeutics' strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "projects", "potential", "outlook" or "continue", or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the approval, timing of commercialization and commercial success of AM-301, Altamira Therapeutics' need for and ability to raise substantial additional funding to continue the development of its product candidates, the timing and conduct of clinical trials of Altamira Therapeutics' product candidates, the clinical utility of Altamira Therapeutics' product candidates, the timing or likelihood of regulatory filings and approvals, Altamira Therapeutics' intellectual property position and Altamira Therapeutics' financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Altamira Therapeutics' capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Altamira Therapeutics' Annual Report on Form 20-F for the year ended December 31, 2020, and in Altamira Therapeutics' other filings with the SEC, which are available free of charge on the Securities Exchange Commission's website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira Therapeutics or to persons acting on behalf of Altamira Therapeutics are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira Therapeutics does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.

Investor contact:
Stephen Kilmer
(647) 872-4849
[email protected]

SOURCE: Altamira Therapeutics Ltd.

Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comAltamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, announced today that it has entered into an exclusive licensing and distribution agreement (the "Agreement") for Bentrio(TM), its nasal spray for protection against airborne viruses and allergens, with Nuance Pharma Ltd. ("Nuance") in Chinese Mainland, Hong Kong, Macau and South Korea (the "Territory").

Notifi Network, Inc, a messaging layer for Web3, announced a $2.5 million pre-seed round…

The post Notifi announces $2.5M pre-seed round appeared first on Coin Journal.